Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
Primary Purpose
Schizophrenia
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
risperidone
olanzapine
quetiapine
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria: hospitalized for schizophrenia Exclusion Criteria: none
Sites / Locations
Outcomes
Primary Outcome Measures
PANSS
Retention.
Secondary Outcome Measures
EPS, TD.
Full Information
NCT ID
NCT00237861
First Posted
October 7, 2005
Last Updated
June 5, 2014
Sponsor
Yale University
Collaborators
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT00237861
Brief Title
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
Official Title
Effectiveness of Atypical Vs Conventional Antipsychotics
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
December 2002 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute of Mental Health (NIMH)
4. Oversight
5. Study Description
Brief Summary
This study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.
Detailed Description
At seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. Medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. Patients were followed for one year after discharge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
risperidone
Intervention Type
Drug
Intervention Name(s)
olanzapine
Intervention Type
Drug
Intervention Name(s)
quetiapine
Primary Outcome Measure Information:
Title
PANSS
Title
Retention.
Secondary Outcome Measure Information:
Title
EPS, TD.
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hospitalized for schizophrenia
Exclusion Criteria:
none
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott W Woods, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
We'll reach out to this number within 24 hrs